JP2008526764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526764A5 JP2008526764A5 JP2007549646A JP2007549646A JP2008526764A5 JP 2008526764 A5 JP2008526764 A5 JP 2008526764A5 JP 2007549646 A JP2007549646 A JP 2007549646A JP 2007549646 A JP2007549646 A JP 2007549646A JP 2008526764 A5 JP2008526764 A5 JP 2008526764A5
- Authority
- JP
- Japan
- Prior art keywords
- primary
- epitope
- mhc
- immunogen
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 35
- 230000002163 immunogen Effects 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 241001465754 Metazoa Species 0.000 claims 8
- 230000000091 immunopotentiator Effects 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 7
- 210000004324 lymphatic system Anatomy 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 210000001165 lymph node Anatomy 0.000 claims 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 241001115402 Ebolavirus Species 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000724205 Rice stripe tenuivirus Species 0.000 claims 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000002766 immunoenhancing effect Effects 0.000 claims 1
- 230000002434 immunopotentiative effect Effects 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64082104P | 2004-12-29 | 2004-12-29 | |
| PCT/US2005/047442 WO2006071990A2 (en) | 2004-12-29 | 2005-12-29 | Methods to bypass cd+4 cells in the induction of an immune response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008526764A JP2008526764A (ja) | 2008-07-24 |
| JP2008526764A5 true JP2008526764A5 (enExample) | 2009-02-26 |
Family
ID=36615526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007549646A Pending JP2008526764A (ja) | 2004-12-29 | 2005-12-29 | 免疫応答の誘導におけるｃｄ４＋細胞の回避方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8703142B2 (enExample) |
| EP (1) | EP1838342A2 (enExample) |
| JP (1) | JP2008526764A (enExample) |
| AU (1) | AU2005321905A1 (enExample) |
| CA (1) | CA2592972A1 (enExample) |
| IL (1) | IL184276A0 (enExample) |
| MX (1) | MX2007008010A (enExample) |
| SG (1) | SG158155A1 (enExample) |
| WO (1) | WO2006071990A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| CA2612516C (en) | 2005-06-17 | 2015-03-24 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| US7511119B2 (en) | 2005-06-17 | 2009-03-31 | Mannkind Corporation | PRAME peptide analogues |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CA2657849A1 (en) | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| US20080014211A1 (en) * | 2006-07-14 | 2008-01-17 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes |
| EP2129389B1 (en) * | 2007-02-15 | 2014-10-08 | MannKind Corporation | A method for enhancing t cell response |
| EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| JP2010528591A (ja) * | 2007-05-23 | 2010-08-26 | マンカインド コーポレイション | マルチシストロン性ベクター及びそれらの設計方法 |
| EP2167537A2 (en) | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Compiled methods for analysing and sorting samples |
| WO2009039854A2 (en) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
| WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| US20110195090A1 (en) * | 2008-10-11 | 2011-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Method of making a vaccine |
| WO2011050344A2 (en) | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| MX360823B (es) | 2011-05-24 | 2018-11-16 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacunas individualizadas para el cancer. |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| JP6484558B2 (ja) | 2012-11-28 | 2019-03-13 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ | 癌ワクチンの組み合せ物 |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| WO2015199617A1 (en) * | 2014-06-24 | 2015-12-30 | National University Of Singapore | A monoclonal antibody with t-cell receptor-like specificity that targets epstein-barr infected human tumour cells based on their expression of ebna1 |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| CN107921127B (zh) * | 2015-05-22 | 2022-04-08 | 纪念斯隆-凯特琳癌症中心 | 对于prame肽具有特异性的t细胞受体样抗体 |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| US12258373B2 (en) | 2018-12-17 | 2025-03-25 | Immudex Aps | Panel comprising Borrelia MHC multimers |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) * | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| IL133912A0 (en) * | 1997-07-10 | 2001-04-30 | Ctl Immunotherapies Corp | A method of inducing ctl response |
| US6994851B1 (en) * | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US6709844B1 (en) * | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
| US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| CA2350911A1 (en) * | 1998-11-16 | 2000-05-25 | Board Of Regents, The University Of Texas System | Hiv-specific t-cell induction |
| EP1267618A1 (en) * | 2000-03-28 | 2003-01-02 | The Regents Of The University Of California | Methods for increasing a cytotoxic t lymphocyte response in vivo |
| DE60142615D1 (de) * | 2000-04-28 | 2010-09-02 | Mannkind Corp | Epitop-synchronisierung in antigen präsentierenden zellen |
| US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| EP1372736A4 (en) * | 2001-03-07 | 2004-11-17 | Mannkind Corp | PREPARATIONS AGAINST CANCER FORMATION |
| WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| CN101024842A (zh) * | 2001-11-07 | 2007-08-29 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
| CN1691964A (zh) | 2002-09-06 | 2005-11-02 | 曼康公司 | 表位序列 |
| ATE546153T1 (de) * | 2003-06-17 | 2012-03-15 | Mannkind Corp | Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen |
| MXPA05013973A (es) * | 2003-06-17 | 2006-03-02 | Mannkind Corp | Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. |
| US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| JP2008503494A (ja) * | 2004-06-17 | 2008-02-07 | マンカインド コーポレイション | 診断方法を治療方法と統合することによる免疫療法の効力改善 |
| US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| EP2332971B1 (en) * | 2004-06-17 | 2016-02-17 | MannKind Corporation | Epitope analogs |
| AU2005321898B2 (en) * | 2004-12-29 | 2012-07-19 | Mannkind Corporation | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
| EP2351576A1 (en) * | 2004-12-29 | 2011-08-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| KR101294290B1 (ko) * | 2004-12-29 | 2013-08-07 | 맨카인드 코포레이션 | 예방 또는 치료를 위해 제ｉ류 주조직 적합성복합체〔ｍｈｃ〕-제한 에피토프에 대한 면역 반응을 유발,향상 및 지속하는 방법 |
| KR20080033271A (ko) * | 2005-06-17 | 2008-04-16 | 맨카인드 코포레이션 | 암종을 위한 다가 동반이행 및 증폭형 면역치료제 |
| CA2612516C (en) * | 2005-06-17 | 2015-03-24 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| US7511119B2 (en) * | 2005-06-17 | 2009-03-31 | Mannkind Corporation | PRAME peptide analogues |
| US20080014211A1 (en) * | 2006-07-14 | 2008-01-17 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes |
-
2005
- 2005-12-29 EP EP05855931A patent/EP1838342A2/en not_active Withdrawn
- 2005-12-29 AU AU2005321905A patent/AU2005321905A1/en not_active Abandoned
- 2005-12-29 MX MX2007008010A patent/MX2007008010A/es not_active Application Discontinuation
- 2005-12-29 WO PCT/US2005/047442 patent/WO2006071990A2/en not_active Ceased
- 2005-12-29 US US11/323,520 patent/US8703142B2/en not_active Expired - Fee Related
- 2005-12-29 SG SG200908487-2A patent/SG158155A1/en unknown
- 2005-12-29 JP JP2007549646A patent/JP2008526764A/ja active Pending
- 2005-12-29 CA CA002592972A patent/CA2592972A1/en not_active Abandoned
-
2007
- 2007-06-28 IL IL184276A patent/IL184276A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526764A5 (enExample) | ||
| Barnett et al. | Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit | |
| Corey et al. | Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen | |
| Cristillo et al. | Induction of mucosal and systemic antibody and T-cell responses following prime–boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations | |
| Fast et al. | Human trials of experimental AIDS vaccines | |
| Jiang et al. | CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides | |
| Zolla-Pazner et al. | Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines | |
| Ratner | A role for an HTLV-1 vaccine? | |
| Karlas et al. | Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection | |
| US8338582B2 (en) | Anti-HIV immunogens and methods for inducing an immune response | |
| Flynn et al. | Factors influencing cellular immune responses to feline immunodeficiency virus induced by DNA vaccination | |
| Koff et al. | Human trials of AIDS vaccines: current status and future directions | |
| Lifson et al. | Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity against intrarectal challenge | |
| Flynn et al. | Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain | |
| Edgeworth et al. | Vaccine development against HIV-1: current perspectives and future directions | |
| Luo et al. | Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination | |
| Stott | Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines | |
| Lockey et al. | Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees | |
| Mohan et al. | Comparative mucosal immunogenicity of HIV gp41 membrane-proximal external region (MPER) containing single and multiple repeats of ELDKWA sequence with defensin peptides | |
| Tramont et al. | Progress in the development of an HIV vaccine | |
| Temchura et al. | The two faces of vaccine-induced immune response: protection or increased risk of HIV infection?! | |
| Bazhan et al. | A synergistic effect of a combined bivalent DNA–protein anti-HIV-1 vaccine containing multiple T-and B-cell epitopes of HIV-1 proteins | |
| Ruffin et al. | Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011 | |
| Silvera et al. | Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques | |
| CN107224578B (zh) | Hiv疫苗及其制备方法 |